Severe COPD with emphysema and frequent exacerbations

Severe COPD (FEV1 below 50% predicted) with emphysema phenotype, chronic bronchitis, and two or more exacerbations per year. GOLD 2024 base therapy is triple inhaled: LABA + LAMA + ICS. With persistent exacerbations, roflumilast (a PDE-4 inhibitor in chronic bronchitis) or long-term azithromycin (a macrolide with anti-inflammatory action) is added.

ICD-10 J44.11 drug

Also known as: GOLD group D COPD

Drugs used for this condition

BRoflumilastSecond line · Selective phosphodiesterase-4 (PDE-4) inhibitorAdd-on therapy in severe COPD with frequent-exacerbator chronic bronchitis phenotype per GOLD 2024. Dose 500 mcg once daily. REACT and RE2SPOND showed 15–20% reduction in exacerbations in patients on triple inhaled therapy (LABA + LAMA + ICS). Not used as monotherapy or replacement for inhaled foundation therapy. Often poorly tolerated due to nausea, diarrhea, and weight loss.

How to read tiers A–F

Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit